Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00359970 |
|
Recruitment Status :
Completed
First Posted : August 3, 2006
Last Update Posted : June 19, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In a previous study azithromycin proved as efficacious as levofloxacin in the treatment of travelers' diarrhea in Mexico. Because the addition of loperamide to some antibiotics (e.g., trimethoprim-sulfamethoxazole and ofloxacin) has proven more efficacious than antibiotic alone in the treatment of travelers' diarrhea, we decided to study the addition of loperamide to azithromycin.
US adults with acute diarrhea in Guadalajara Mexico were randomized to receive azithromycin in two different doses or loperamide plus azithromycin.
The duration of diarrhea was shorter (11 hours) in the combination-treated group compared to the antibiotic-treated groups (34 hours). The percentage of subjects continuing to pass 6 or more unformed stools in the first 24 hours was less (1.7%) in the combination-treated group than in the antibiotic-treated groups (20%).
We feel loperamide should routinely be added to an antibiotic to optimize treatment of travelers' diarrhea.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diarrhea | Drug: Azithromycin 500 mg Drug: Azithromycin 1000 mg Drug: Loperamide Other: Placebo | Phase 4 |
Background. The combination of loperamide and trimethoprim-sulfamethoxazole or a fluoroquinolone has proven to be more efficacious than the antimicrobial agent alone in the treatment of travelers' diarrhea. We set out to prove loperamide plus azithromycin was more efficacious that azithromycin alone.
Methods. During the summers of 2002-3, 176 US adults recently arrived in Guadalajara, Mexico were enrolled in a prospective, double-blinded, randomized trial of the treatment of acute diarrhea. Subjects received single doses (1000 mg or 500 mg) of azithromycin or a single 500 mg dose of azithromycin plus loperamide. Subjects gave a pre and post treatment stool sample for analysis and maintained daily diaries of symptoms and passage of stools.
Results. The MIC90 of azithromycin for all E. coli and Shigella was 0.03 and 4 µg/ml with eradication rates in day 5 stools of 88% and 100%, respectively. The duration of diarrhea was significantly (p=0.0002) shorter following treatment with azithromycin plus loperamide (11 h) than with either dose of azithromycin alone (34 h). In the first 24 h the average number of unformed stools passed was 3.4 (azithromycin-alone) and 1.2 (combination) for a significant (p<0.0001) difference of 2.2 unformed stools. This difference equated with 20% of azithromycin-treated subjects continuing to pass 6 or more unformed stools in the first 24 h post treatment compared with only 1.7% of combination-treated subjects.
Conclusions. For the treatment of travelers' diarrhea in an E. coli predominant region of the world a single 500 mg dose of azithromycin appeared as effective as a 1000 mg dose. Loperamide plus 500 mg azithromycin was safe and more effective than either dose of azithromycin. To realize the substantial clinical benefit that accrues to a subset of subjects, we feel loperamide should routinely be used in combination with an antimicrobial agent to treat travelers' diarrhea.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 176 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone |
| Study Start Date : | June 2002 |
| Actual Primary Completion Date : | August 2003 |
| Actual Study Completion Date : | August 2003 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Azithromycin 500 mg plus Placebo
a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
|
Drug: Azithromycin 500 mg
A single 500 mg dose at the start of treatment
Other Name: Zithromax, Zmax Other: Placebo A single loading dose at the start of treatment and then a dose after each loose stool |
|
Active Comparator: Azithromycin 1000 mg plus Placebo
a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
|
Drug: Azithromycin 1000 mg
A single 1000 mg dose at the start of treatment
Other Name: Zithromax, Zmax Other: Placebo A single loading dose at the start of treatment and then a dose after each loose stool |
|
Experimental: Azithromycin 500 mg plus Loperamide
a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
|
Drug: Azithromycin 500 mg
A single 500 mg dose at the start of treatment
Other Name: Zithromax, Zmax Drug: Loperamide A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
Other Name: IModium, Loperamide HCl |
- Hours from beginning treatment to passage of last unformed stool [ Time Frame: subjects recorded the time and form of all stools passed during a 4 day observation period ]
- Number of unformed stools passed per 24 hour period [ Time Frame: 24 hours after treatment ]
- Number of subjects with symptoms of enteric disease per 24 hour period [ Time Frame: 24 hours after treatment ]Symptoms of enteric disease include nausea, vomiting, abdominal cramps, gas, urgency, and tenesmus.
- Number of treatment failures [ Time Frame: 72 hours after treatment ]Treatment failure is defined as persisting ill after 72 hours
- Percent of subjects in whom enteropathogen isolated from an enrollment stool sample was eradicated from a day 5 stool [ Time Frame: 5 days after treatment ]
- Percent of subjects continuing to pass 3 or more (enrollment criteria) unformed stools in a 24 hour period [ Time Frame: 24 hours after treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible subjects included men or women, recently arrived in Mexico, at least 18 years of age, who developed acute diarrhea, which was defined as passage of 3 or more unformed stools in the preceding 24 hours accompanied by one or more signs or symptoms of enteric infection (e.g., nausea, vomiting, abdominal cramps, tenesmus, passage of grossly bloody stools or fecal urgency) with a duration of illness of less than or equal to 72 hours.
Exclusion Criteria:
- Exclusion criteria included pregnancy, breast feeding, an unstable medical condition, taking two or more doses of an antidiarrheal medication in the 24 hours before enrollment or any number of doses of symptomatic therapy within 2 hours of enrollment, or receiving an antimicrobial drug with expected activity against enteric bacterial pathogens within 7 days prior to enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00359970
| Mexico | |
| University of Texas Enteric Disease Research Clinics | |
| Guadalajara, Jalisco, Mexico | |
| Principal Investigator: | Charles D. Ericsson, MD | University of Texas Medical School at Houston |
| Responsible Party: | Charles D Ericsson, Professor and Dr. and Mrs. Carl V. Vartian Professor in Infectious Diseases, The University of Texas Health Science Center, Houston |
| ClinicalTrials.gov Identifier: | NCT00359970 |
| Other Study ID Numbers: |
HSC-MS-02-082 |
| First Posted: | August 3, 2006 Key Record Dates |
| Last Update Posted: | June 19, 2015 |
| Last Verified: | June 2015 |
|
Diarrhea Travel Travelers' diarrhea Azithromycin |
Loperamide Treatment Antibiotic |
|
Diarrhea Signs and Symptoms, Digestive Azithromycin Loperamide |
Antidiarrheals Anti-Bacterial Agents Anti-Infective Agents Gastrointestinal Agents |